Llwytho...
The role of fedratinib for the treatment of patients with primary or secondary myelofibrosis
Myelofibrosis (MF) is a chronic myeloid neoplasm characterized by either primary myelofibrosis, or secondary MF following essential thrombocythemia or polycythemia vera. Historically, therapy has been symptom directed; however, in 2011, the first janus kinase inhibitor (JAK-i) – ruxolitinib – was ap...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ther Adv Hematol |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SAGE Publications
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7232117/ https://ncbi.nlm.nih.gov/pubmed/32477483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720925201 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|